Sodium Selenate Treatment for Probable Behavioural Variant Fronto-temporal Dementia

Subject area of study: 
Behavioural Variant Fronto-temporal Dementia
Title of study: 
Sodium Selenate Treatment for Probable Behavioural Variant Fronto-temporal Dementia
Brief outline of the study: 

This research project is looking at whether the trial drug, sodium selenate decreases the rate of brain shrinkage in patients with behavioural variant Fronto-temporal dementia (bvFTD). Participants are randomly assigned to one of two groups. One group will receive the study drug, sodium selenate, and the other group will receive a placebo.
Participation in this research involves attending appointments at the study doctor’s clinic up to ten times over 15 months, taking the study drug (or placebo) three times a day and maintaining a Diary Card (recording any side effects or medication changes).
The appointments will include MRI & PET scans, two lumbar punctures, physical & neurological examinations, blood tests, and cognitive tests & questionnaires.
We are currently recruiting participants with bvFTD to take part in this study across four sites, three in Melbourne and one in Sydney.

Department: 
Neuroscience
Recruitment start date: 
Sun, 04/04/2021
Recruitment end date: 
Tue, 01/07/2025
Contact person title: 
Dr
Contact person first name: 
Lucy
Contact person last name: 
Vivash
Contact email: 
selenate@alfred.org.au
Contact phone number: 
(03) 9903 0860
Ethics Committee Project Number: 
609/19
Do you have advertising approval?: 
Yes
Approved by: 
Alfred